SM
SCNI

Sabby Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Sabby Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,783
Closed -$49.6K – 59
2024
Q2 		$49.6K Sell
1,783
-748
-30% -$31K 0.03% 32
2024
Q1 		$131K Buy
2,531
+324
+15% +$16.7K 0.08% 29
2023
Q4 		$131K Sell
2,207
-243
-10% -$16.7K 0.13% 32
2023
Q3 		$213K Buy
2,450
+541
+28% +$69.3K 0.16% 37
2023
Q2 		$269K Sell
1,909
-1,351
-41% -$233K 0.22% 41
2023
Q1 		$704K Buy
3,260
+1,054
+48% +$260K 0.61% 15
2022
Q4 		$653K Buy
+2,206
New +$1.66M 0.57% 21
2017
Q4 		– Sell
-19
Closed -$139K – 183
2017
Q3 		$139K Buy
+19
New +$156K 0.01% 134

Other funds holding SCNI

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sabby Management's SCNI Position: Q3 2024 in Review

Sabby Management sold out of Scinai Immunotherapeutics (SCNI) in Q3 2024, closing a stake of 1,783 shares — an estimated $49.6K sold.

Sabby Management first reported a position in SCNI in Q3 2017 and held it in 8 quarters. The position peaked at $704K in Q1 2023. 5 funds tracked by Wall St. Rank hold SCNI as of Q3 2024.

  • Sabby Management reported no remaining Scinai Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Sabby Management sold 1,783 Scinai Immunotherapeutics shares in Q3 2024, an estimated $49.6K.
  • Sabby Management first reported a position in Scinai Immunotherapeutics in Q3 2017 and held it in 8 quarters.
  • Sabby Management's Scinai Immunotherapeutics position peaked at $704K in Q1 2023.
  • 5 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2024.

Based on Sabby Management's 13F filing for Q3 2024, filed 14 Nov 2024.